Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 55Neoplasms 31Unspecified Adult Solid Tumor, Protocol Specific 30Pancreatic Neoplasms 28Neoplasm Metastasis 24Colonic Neoplasms 23Stomach Neoplasms 22Rectal Neoplasms 20Neuroblastoma 15Lung Neoplasms 13Esophageal Neoplasms 12Glioblastoma 11Central Nervous System Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Brain Neoplasms 11Astrocytoma 11Small Cell Lung Carcinoma 9Glioma 9Oligodendroglioma 8Gliosarcoma 8Breast Neoplasms 8Esophageal Squamous Cell Carcinoma 7Adenocarcinoma 7Unspecified Childhood Solid Tumor, Protocol Specific 6Ovarian Neoplasms 6Gallbladder Neoplasms 6Carcinoma, Hepatocellular 6Bile Duct Neoplasms 6Triple Negative Breast Neoplasms 5Solid Tumor 5

Interventions

Gemcitabine 3Docetaxel 3belinostat 2Fluorouracil 2Bevacizumab 2venetoclax 1toripalimab 1tanespimycin 1ivosidenib 1itacitinib 1durvalumab 1capivasertib 1birinapant 1baricitinib 1Zoledronic Acid 1Thalidomide 1Taxes 1Radiotherapy 1Paclitaxel 1Medicare Part B 1Leucovorin 1Irinotecan 1Immunoglobulin G 1INCB039110 1IFL protocol 1Filgrastim 1Disulfides 1Cisplatin 1Chemotherapy, Adjuvant 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Chondrosarcoma × Irinotecan × Clear all
NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡